Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)

v3.22.1
Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Mar. 31, 2022
Mar. 31, 2021
Earnings Per Share                
Net earnings, including noncontrolling interest $ 60,144 $ 72,059 $ 68,981 $ 45,402 $ 46,144 $ 33,395 $ 201,184 $ 124,941
Net earnings (loss) attributable to noncontrolling interest (595)     (380)     (9,343) (509)
Net earnings attributable to Bio-Techne 60,739     45,782     210,527 125,450
Income allocated to participating securities (25)     (27)     (95) (77)
Income available to common shareholders $ 60,714     $ 45,755     $ 210,432 $ 125,373
Basic (in shares) 39,272     38,856     39,225 38,693
Basic (in dollars per share) $ 1.55     $ 1.18     $ 5.36 $ 3.24
Income allocated to participating securities $ (25)     $ (27)     $ (95) $ (77)
Income available to common shareholders $ 60,714     $ 45,755     $ 210,432 $ 125,373
Dilutive effect of stock options and restricted stock units (in shares) 1,697     1,820     1,848 1,612
Weighted-average common shares outstanding - diluted 40,969     40,676     41,073 40,305
Diluted (in dollars per share) $ 1.48     $ 1.12     $ 5.12 $ 3.11